Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Blood-brain barrier transport of amyloid beta peptides in efflux pump knock-out animals evaluated by in vivo optical imaging.

Zhang W, Xiong H, Callaghan D, Liu H, Jones A, Pei K, Fatehi D, Brunette E, Stanimirovic D.

Fluids Barriers CNS. 2013 Feb 25;10(1):13. doi: 10.1186/2045-8118-10-13.

2.

ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.

Do TM, Noel-Hudson MS, Ribes S, Besengez C, Smirnova M, Cisternino S, Buyse M, Calon F, Chimini G, Chacun H, Scherrmann JM, Farinotti R, Bourasset F.

J Alzheimers Dis. 2012;30(1):155-66. doi: 10.3233/JAD-2012-112189.

PMID:
22391220
3.

ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.

Xiong H, Callaghan D, Jones A, Bai J, Rasquinha I, Smith C, Pei K, Walker D, Lue LF, Stanimirovic D, Zhang W.

J Neurosci. 2009 Apr 29;29(17):5463-75. doi: 10.1523/JNEUROSCI.5103-08.2009.

4.

Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).

Do TM, Dodacki A, Alata W, Calon F, Nicolic S, Scherrmann JM, Farinotti R, Bourasset F.

J Alzheimers Dis. 2016;49(2):287-300. doi: 10.3233/JAD-150350.

PMID:
26484906
5.

PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.

Vlaming ML, Läppchen T, Jansen HT, Kivits S, van Driel A, van de Steeg E, van der Hoorn JW, Sio CF, Steinbach OC, DeGroot J.

Nucl Med Biol. 2015 Nov;42(11):833-41. doi: 10.1016/j.nucmedbio.2015.07.004. Epub 2015 Jul 15.

PMID:
26264927
6.

Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.

Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM.

Cancer Res. 2004 May 1;64(9):3296-301.

7.

[(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.

Wanek T, Traxl A, Bankstahl JP, Bankstahl M, Sauberer M, Langer O, Kuntner C.

Nucl Med Biol. 2015 Jul;42(7):585-9. doi: 10.1016/j.nucmedbio.2015.03.004. Epub 2015 Mar 18.

PMID:
25823393
8.

Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.

Poller B, Wagenaar E, Tang SC, Schinkel AH.

Mol Pharm. 2011 Apr 4;8(2):571-82. doi: 10.1021/mp1003898. Epub 2011 Mar 4.

PMID:
21309545
9.

MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer's amyloid-beta peptides--implications for the mechanisms of Abeta clearance at the blood-brain barrier.

Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, Warzok RW, Vogelgesang S.

Brain Pathol. 2007 Oct;17(4):347-53. Epub 2007 Jul 4.

PMID:
17610523
10.

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH.

Int J Cancer. 2012 Jan 1;130(1):223-33. doi: 10.1002/ijc.26000. Epub 2011 Apr 7.

11.

Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.

Poller B, Iusuf D, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Drug Metab Dispos. 2011 May;39(5):729-35. doi: 10.1124/dmd.110.037317. Epub 2011 Jan 31.

12.

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).

Kort A, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Pharmacol Res. 2015 Dec;102:200-7. doi: 10.1016/j.phrs.2015.09.003. Epub 2015 Sep 8.

PMID:
26361725
13.

Beta-Amyloid Downregulates MDR1-P-Glycoprotein (Abcb1) Expression at the Blood-Brain Barrier in Mice.

Brenn A, Grube M, Peters M, Fischer A, Jedlitschky G, Kroemer HK, Warzok RW, Vogelgesang S.

Int J Alzheimers Dis. 2011;2011:690121. doi: 10.4061/2011/690121. Epub 2011 May 29.

14.

Apical-to-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein.

Candela P, Gosselet F, Saint-Pol J, Sevin E, Boucau MC, Boulanger E, Cecchelli R, Fenart L.

J Alzheimers Dis. 2010;22(3):849-59. doi: 10.3233/JAD-2010-100462. Erratum in: J Alzheimers Dis. 2011;23(4):763.

PMID:
20858979
15.

Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.

Lee YJ, Kusuhara H, Jonker JW, Schinkel AH, Sugiyama Y.

J Pharmacol Exp Ther. 2005 Jan;312(1):44-52. Epub 2004 Sep 24.

16.

Abcb1a but not Abcg2 played a predominant role in limiting the brain distribution of Huperzine A in mice.

Li J, Yue M, Zhou D, Wang M, Zhang H.

Food Chem Toxicol. 2017 Jun 3. pii: S0278-6915(17)30313-7. doi: 10.1016/j.fct.2017.06.005. [Epub ahead of print]

PMID:
28587984
17.

Beta amyloid effects on expression of multidrug efflux transporters in brain endothelial cells.

Kania KD, Wijesuriya HC, Hladky SB, Barrand MA.

Brain Res. 2011 Oct 18;1418:1-11. doi: 10.1016/j.brainres.2011.08.044. Epub 2011 Aug 23.

PMID:
21920506
18.

Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV.

J Cereb Blood Flow Metab. 2007 May;27(5):909-18. Epub 2006 Nov 1.

19.
20.

Supplemental Content

Support Center